Business Wire

THALES

7.10.2019 07:47:05 CEST | Business Wire | Press release

Share
The Cyberthreat Handbook: Thales and Verint Release Their "Who's Who" of Cyberattackers

Powered by the cutting-edge technologies and products of Thales and Verint, the two companies are pleased to present The Cyberthreat Handbook , a report of unprecedented scope designed to provide a classification and basis for further investigation of major groups of cyberattackers, including cybercriminals, cyberterrorists, hacktivist groups and state-sponsored hackers. As part of the strategic partnership to create a comprehensive, state-of-the art Cyber Threat Intelligence technologies, threat intelligence analysts from Thales and Verint have worked together to provide this unique 360° view of the cyberthreat landscape, with detailed descriptions of the activities of about sixty particularly significant groups, including their tactics and techniques, their motives and the sectors targeted from analysis of multiple data sources such as web and threat intelligence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191006005044/en/

As cybersecurity grows in importance, Thales and Verint have worked together to find out more about cyberattackers and the techniques they employ, the purpose being to help organisations in the private and public sectors to better detect and anticipate future attacks. The cyberthreat landscape is extremely diversified, and knowing one's enemies can be particularly complex in this world of subterfuge and deception.

"The Thales and Verint teams are immensely proud to release this report today as part of its technology and domain expertise cooperation. Unique in its breadth and depth, it is the culmination of many months of research, investigation and painstaking analysis and correlation of relevant data. As cyberthreats proliferate and evolve, cybersecurity clearly has a major role to play, particularly for critical infrastructure providers. It is our duty to analyse, understand and describe the techniques employed by cyberattackers so that our customers and all other businesses and organisations are better prepared to detect and anticipate future attacks." Marc Darmon, Executive Vice President, Secure Communications and Information Systems, Thales

“Joining forces with Thales strengthens our mutual ability to deliver comprehensive knowledge of potential threats, and thus provide the necessary cyber security protection,” said Elad Sharon, President, Verint Cyber Intelligence Solutions. “Verint Cyber Intelligence leverages years of intelligence domain expertise, embedded within investigation methodologies and technologies critical to prevent cyber-attacks before they get into the gateway of the organization. This report generates unique insights and knowldege to cyber and security experts to mitigate and foresee cyberattacks”.

Analysts from Thales and Verint have defined four major categories of attackers based on their motives and ultimate objectives. Out of approximately sixty major groups of attackers analysed, 49% are state-sponsored groups often aiming to steal sensitive data from targets of geopolitical interest. 26% are ideologically motivated hacktivists, closely followed by cybercriminals (20%) who are driven by financial gain. In fourth position, cyberterrorists account for 5% of the groups analysed.

All the world's major economic, political and military powers are priority targets of cyberattackers. The 12 countries in the world with the highest GDP are all at the top of the list of targets, headed by the United States, Russia, the European Union (particularly the United Kingdom, France and Germany) and China, followed by India, South Korea and Japan.

The sectors most targeted by these major attacks are States and their defence capabilities, followed by the financial sector, energy and transportation. Attacks towards medias and health industry are increasing fast.

Last but not least, a growing number of groups of attackers are now focusing on vulnerabilities in the supply chain, and in particular on smaller partners, suppliers and service providers that are used as trojans to access major targets.

Notes to editors - Methodology

This report does not set out to be an exhaustive inventory of cyberattackers but rather to shed light on the major groups of attackers that have been identified over the last 10 years. The sixty-odd groups and 490 attack campaigns analysed in the report were selected because they are considered emblematic in terms of their impact, attack techniques, scope, target profiles, historical nature or recent emergence. The entire analysis is based on the MITRE Att&ck matrix , a knowledge base of adversary tactics and techniques. More details can be found in the press kit.

 

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto).

 

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments

 

About Verint Systems Inc.

Verint® (Nasdaq: VRNT) is a global leader in Actionable Intelligence® solutions with a focus on customer engagement optimisation, security intelligence, and fraud, risk and compliance. Today, over 10,000 organisations in more than 180 countries—including over 80 percent of the Fortune 100—count on intelligence from Verint solutions to make more informed, effective and timely decisions. Learn more about how we’re creating A Smarter World with Actionable Intelligence® at www.verint.com .

 

About Verint Cyber Intelligence.

Verint Cyber Intelligence is a leading global provider of security and intelligence data mining software. Our broad and deep product portfolio is deployed in over 100 countries, helping government, critical infrastructure and enterprise organizations to neutralize and prevent terror, crime and cyber threats for a safer world.

PLEASE VISIT

Thales Group
Download photos
Download the report

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye